BioMed Research International

Research Article

Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01

Table 3

Relapses and deaths in paediatric patients with ALL who were younger than 16 years of age and who were treated at the paediatric haematology service of the specialist “La Raza” IMSS Medical Centre.
TotalRelapse
(at 3 years)		Not Relapse
(at 3 years)		Relapse
(at 5 year)		No Relapse
(at 5 years)		Death
(at 3 years)		Lives
(at 3 years)		Death
(at 5 years)		Lives
(at 5 years)
(%) (%) (%) (%) (%) (%) (%) (%) (%)
Sex         
 Male (%)167 (100)41 (24.6)126 (75.4)51 (30.5)116 (69.5)48 (28.7)119 (71.3)54 (32.3)113 (67.7)
 Female (%)135 (100)26 (19.3)109 (80.7)28 (20.7)107 (79.3)44 (32.6)91 (67.4)52 (38.5)83 (61.5)
Age (years)         
 <11 (100)1 (100)0 (0.0)1 (100)0 (0.0)0 (0)1 (100)1 (100)0 (0.0)
 1–5 122 (100)25 (20.5)97 (79.5)31 (25.4)91 (74.0)29 (23.8)93 (76.2)35 (28.7)87 (71.3)
 5.1–9.9966 (100)17 (25.8)49 (74.2)19 (28.8)47 (71.2)22 (33.3)44 (66.7)26 (39.4)40 (60.6)
 ≥10 113 (100)24 (21.2)89 (78.7)28 (24.8)85 (75.2)41 (36.3)72 (63.7)44 (38.9)69 (61.1)
Lineage         
 B 279 (100)73 (22.6)216 (77.4)75 (26.9)204 (73.1)81 (29.0)198 (71.0)94 (33.7)185 (66.3)
 T 23 (100)4 (17.4)19 (82.6)4 (17.9)19 (82.6)11 (47.8)12 (52.2)12 (52.2)11 (47.8)
Risk group         
 Standard146 (100)37 (25.3)109 (74.7)44 (30.1)102 (69.9)44 (30.1)102 (69.9)48 (32.9)98 (67.1)
 High156 (100)30 (19.2)126 (80.8)35 (22.4)121 (77.6)48 (30.8)108 (69.2)58 (37.2)98 (62.8)
WBC (1 × 109/L)         
 <10147 (100)34 (23.1)113 (76.9)38 (25.9)109 (74.1)40 (27.2)107 (72.8)43 (29.3)104 (70.7)
 10–20 48 (100)10 (20.8)38 (79.2)14 (29.2)34 (70.8)18 (37.5)30 (62.5)20 (41.7)28 (58.3)
 20–5034 (100)3 (8.8)31 (91.2)5 (14.7)29 (85.3)11 (32.4)23 (67.6)12 (35.3)22 (64.7)
 50–100 000 27 (100)7 (25.9)20 (74.1)8 (29.6)19 (70.4)6 (22.2)21 (77.8)10 (37.0)17 (63.0)
 ≥10046 (100)13 (28.3)33 (71.7)14 (30.4)32 (69.6)17 (37.0)29 (63.0)21 (45.7)26 (54.3)